Aims: One of the leading causes of death and disease burden globally is coronary heart disease (CHD). The primary cause of acute coronary syndrome (ACS) is atherosclerotic plaque rupture and thrombus development. The prognosis of ACS patients is also linked to atherosclerotic plaques, inflammatory cell infiltration (lymphocytes, monocytes, and neutrophils), and inflammation indicators. Low serum albumin (SA) levels have been linked to death in ACS patients in earlier research. In our study, we aimed to investigate the association of neutrophil percentage-to-albumin ratio (NPAR) with infarct-related adverse cardiac events (MACE) and infarct-related coronary artery patency (IRA).Methods: The NPAR ratio was calculated based on the past laboratory findings of patients admitted with ACS who underwent coronary angiography (CAG), which were registered in the data system at the time of admission. A total of 87 patients were included in the study. Of these patients, 62 (71%) were non-patent and 25 (29%) were patent IRA patients.Results: NPAR was significantly higher in the non-patent group (19.22±3.14 and 17.14±2.78 p=0.004). In multivariable logistic regression analysis, NPAR p=0.027, odds ratio (OR): 0.787, 95% confidence intervals (CIs): 0.637-0.974 levels were found to be independent predictors of patent IRA. As revealed by the ROC curve analysis, the cut-off value of 17.88 for NPAR predicted the non-patent IRA with a sensitivity of 64% and specificity of 64% (AUC: 0.681; CIs: 0.588-0.809; p=0.008) NPAR was significantly higher in the MACE group (22.83±3.85 and 17.95±2.49 p
Akgümüş et al. (Tue,) studied this question.